Retraction Note to: Mol Cancer 10, 115 (2011)

https://doi.org/10.1186/1476-4598-10-115

The Editor-in-Chief has retracted this article after an investigation by Harvard Medical School and Beth Israel Deaconess Medical Center and additional analysis by the Office of Research Integrity found:

• Reuse and relabelling of the same source bands to falsely represent different experimental results in Figure 3A (first four lanes in the middle row of the left panel representing c-myc expression in nucleus of A375 cell type, and first four lanes in the middle row of the right panel representing c-myc expression in nucleus of SK MEL 5 cell type)

• Reuse and relabelling of the same source bands to falsely represent different experimental results in Figure 5 (sixth to eighth lanes of the middle row representing BCL-XL expression in A375-GSK cells with DOX, and last three lanes of the middle row representing BCL-XL expression in SK MEL 5 S9A)

• Reuse and relabelling of unrelated source bands falsely represent different experimental results in Figure 5 (thirteenth to fifteenth lanes of the top row representing BCL2 expression in SK MEL 5 S9A, and thirteenth to fifteenth lanes of the bottom row representing VINCULIN expression in SK MEL 5 S9A)

James W Mier agrees with this retraction. David J Panka does not agree with this retraction. The Editor-in-Chief has not been able to find a current email address for Qingjun Liu.

Affiliations

1. Division of Hematology-Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

   Qingjun Liu, James W. Mier & David J. Panka

2. Division of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

   Qingjun Liu

1. Qingjun LiuView author publications

   You can also search for this author in PubMed Google Scholar

2. James W. MierView author publications

   You can also search for this author in PubMed Google Scholar

3. David J. PankaView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Panka.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Cite this article

Liu, Q., Mier, J.W. & Panka, D.J. Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer 20, 92 (2021). https://doi.org/10.1186/s12943-021-01378-8

Download citation

• Published: 15 June 2021

• DOI: https://doi.org/10.1186/s12943-021-01378-8